Abivax (NASDAQ:ABVX) Raised to “Hold” at Wall Street Zen

Abivax (NASDAQ:ABVX) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other research analysts have also issued reports on the stock. Morgan Stanley lifted their price target on shares of Abivax from $101.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Citigroup restated a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. Barclays lifted their price target on shares of Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Jefferies Financial Group assumed coverage on shares of Abivax in a research report on Monday, March 16th. They issued a “buy” rating and a $160.00 price target on the stock. Finally, Oddo Bhf restated an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.15.

Abivax Price Performance

NASDAQ ABVX opened at $120.16 on Friday. Abivax has a 12 month low of $5.59 and a 12 month high of $148.83. The firm has a market capitalization of $9.53 billion, a PE ratio of -22.38 and a beta of 1.68. The company’s 50 day simple moving average is $119.10 and its 200 day simple moving average is $115.09.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($1.20) EPS for the quarter. The company had revenue of $0.52 million for the quarter. Sell-side analysts anticipate that Abivax will post -2.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Abivax

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its position in Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after purchasing an additional 369 shares in the last quarter. First Horizon Corp purchased a new position in Abivax during the 3rd quarter worth approximately $36,000. Bank of America Corp DE grew its position in Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares in the last quarter. Hantz Financial Services Inc. purchased a new position in Abivax during the 3rd quarter worth approximately $52,000. Finally, Caitong International Asset Management Co. Ltd grew its position in Abivax by 661.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after purchasing an additional 344 shares in the last quarter. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.